ОПЫТ УСПЕШНОГО ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА У ПАЦИЕНТКИ С ПОЛИАРТИКУЛЯРНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА С ОБЗОРОМ ПРЕДИКТОРОВ ХОРОШЕГО ОТВЕТА НА ПРОВОДИМУЮ ТЕРАПИЮ
А. В. Карасёва, Екатерина Иосифовна Алексеева, Т. М. Дворяковская
{"title":"ОПЫТ УСПЕШНОГО ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА У ПАЦИЕНТКИ С ПОЛИАРТИКУЛЯРНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА С ОБЗОРОМ ПРЕДИКТОРОВ ХОРОШЕГО ОТВЕТА НА ПРОВОДИМУЮ ТЕРАПИЮ","authors":"А. В. Карасёва, Екатерина Иосифовна Алексеева, Т. М. Дворяковская","doi":"10.15690/VSP.V16I4.1779","DOIUrl":null,"url":null,"abstract":"The article presents a case of polyarticular juvenile idiopathic arthritis resistant to methotrexate therapy and nonsteroidal antiinflammatory drugs. The child was prescribed a tumor necrosis factor inhibitor etanercept at a dose of 0.4 mg/kg body weight2 times/week. The treatment with etanercept induced remission of the disease, ensured the function restoration in the joints. The predictors of a good response to etanercept were the younger age, the short course of the disease, the use of a small number of immunosuppressants before prescription of etanercept, the absence of concomitant use of glucocorticosteroids, and the absence of uveitis.","PeriodicalId":10919,"journal":{"name":"Current Paediatrics","volume":"80 1","pages":"321-325"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Paediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15690/VSP.V16I4.1779","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The article presents a case of polyarticular juvenile idiopathic arthritis resistant to methotrexate therapy and nonsteroidal antiinflammatory drugs. The child was prescribed a tumor necrosis factor inhibitor etanercept at a dose of 0.4 mg/kg body weight2 times/week. The treatment with etanercept induced remission of the disease, ensured the function restoration in the joints. The predictors of a good response to etanercept were the younger age, the short course of the disease, the use of a small number of immunosuppressants before prescription of etanercept, the absence of concomitant use of glucocorticosteroids, and the absence of uveitis.